Stockscreener 앱 받기
2.31
2.53%
-0.06
전일 마감가:
$2.37
열려 있는:
$2.35
하루 거래량:
42,194
Relative Volume:
0.50
시가총액:
$11.22M
수익:
$29.57M
순이익/손실:
$-34.68M
주가수익비율:
-0.00326
EPS:
-708.7214
순현금흐름:
$-7.58M
1주 성능:
-17.79%
1개월 성능:
-16.00%
6개월 성능:
-93.09%
1년 성능:
-97.24%
1일 변동 폭
$2.21
$2.35
1주일 범위
$2.17
$2.87
52주 변동 폭
$2.12
$88.77
재규어 헬스 Stock (JAGX) Company Profile
명칭
Jaguar Health Inc
전화
415-371-8300
주소
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
2.31 | 11.22M | 29.57M | -34.68M | -7.58M | -708.72 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
재규어 헬스 Stock (JAGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-07-11 | 개시 | Rodman & Renshaw | Buy |
재규어 헬스 주식(JAGX)의 최신 뉴스
MSN Money - MSN
Jaguar Health (JAGX) Lytham Partners Fall 2025 Investor Conference Summary - Quartr
Jaguar Health (JAGX) Proxy filing Summary - Quartr
Price to book forward of Jaguar Health, Inc. – FWB:1JA1 - TradingView
Jaguar Health stock and its path in specialty pharma. Investors weigh volatile moves - ad-hoc-news.de
Jaguar Health (JAGX) Slides 7.6% as Selling Pressure Tests Key Support ZoneCalendar Spread Trade - dars.gov.et
JAGXJaguar Health Inc Latest SEC Filings - Finviz
JAGUAR HEALTH INC (JAGX) Stock Chart - ChartMill
Jaguar Health to Present at Lytham Partners Fall 2022 Investor Conference on September 28th and at Ladenburg Thalmann 2022 Healthcare Conference on September 29th - ACCESS Newswire
Jaguar Health, Inc. Files 8-K Report on July 1, 2026 – Key Company Information & SEC Disclosure Details - Minichart
Jaguar Health Inc. Q1 2026 Earnings: EPS Falls Far Below Estimates, Stock Edges Higher Despite No Revenue - dars.gov.et
Enterprise value to revenue forward of Jaguar Health, Inc. – NASDAQ:JAGX - TradingView
Jaguar Health (JAGX) completes Series O preferred stock conversion to common shares - Stock Titan
Jaguar Health Company Profile & Introduction - Moomoo
Jaguar Health (JAGX) Showcases Crofelemer Data at ESPGHAN Conference - GuruFocus
Jaguar Health reports crofelemer data for rare pediatric diseases By Investing.com - Investing.com Nigeria
Jaguar Health reports crofelemer data for rare pediatric diseases - Investing.com
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF) - ACCESS Newswire
Jaguar Health says crofelemer cut one child's support needs by 48% - Stock Titan
Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders - ACCESS Newswire
Enterprise value to EBIT forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
Price to earnings forward of Jaguar Health, Inc. – NASDAQ:JAGX - TradingView
Price to earnings forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
Price to book forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
Enterprise value to revenue forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
Jaguar Health shares after reverse split, small-cap biotech stock in the OTC market spotlight - AD HOC NEWS
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing - GlobeNewswire Inc.
Enterprise value to EBITDA forward of Jaguar Health, Inc. – NASDAQ:JAGX - TradingView
Jaguar Health Inc (JAGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
Enterprise value to EBITDA forward of Jaguar Health, Inc. – GETTEX:1JA1 - TradingView
Jaguar Health (JAGX) Announces Conversion of Series O Convertibl - GuruFocus
Jaguar Health Converts Series O Preferred Stock; Advances Crofelemer Program for Rare Intestinal Failure Diseases - Minichart
Series O preferred conversion at Jaguar Health (NASDAQ: JAGX) - Stock Titan
Price to sales forward of Jaguar Health, Inc. – NASDAQ:JAGX - TradingView
Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend - ACCESS Newswire
Jaguar Health's one-time stock dividend converts into 3.209 shares - Stock Titan
Enterprise value to EBIT forward of Jaguar Health, Inc. – GETTEX:1JA1 - TradingView
Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases - ACCESS Newswire
Jaguar Health Inc (JAGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Jaguar Health (JAGX) Submits New Drug Application for Canalevia-CA1 - GuruFocus
Jaguar Health submits drug application for dog diarrhea treatment By Investing.com - Investing.com Australia
Jaguar Health submits drug application for dog diarrhea treatment - Investing.com UK
Jaguar Health explores strategic options, shares react ahead of Nasdaq investor forum - ad-hoc-news.de
Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - ACCESS Newswire
Jaguar Health seeks full FDA approval for dog diarrhea drug - Stock Titan
Jaguar Health Explores Strategic Alternatives Ahead of NDA Filing for Crofelemer Rare Intestinal Failure Drug - Minichart
Jaguar Health (NASDAQ: JAGX) updates release on strategic alternatives - Stock Titan
Jaguar Health (JAGX) Explores Strategic Alternatives for Stockho - GuruFocus
Jaguar Health Explores Strategic Alternatives Ahead of NDA for Rare Intestinal Failure Drug Crofelemer in $1.1B Market 1 – Minichart - Minichart
Jaguar Health reviews strategic alternatives ahead of Crofelemer NDA filing - MSN
재규어 헬스 (JAGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):